January 17, 2025European Heart Journal
The decalogue of the 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society consensus document on catheter and surgical ablation of atrial fibrillation
Why the study?
Recent clinical trial data and technological advancements in AF ablation created a need to provide updated clinical guidance for managing patients undergoing AF ablation.
Does catheter ablation prevent arrhythmia recurrences and improve symptoms compared to antiarrhythmic drugs in symptomatic, AAD-naïve patients with recurrent paroxysmal AF?
Key Points
- The aim is to summarize the latest findings and provide updated clinical guidelines for atrial fibrillation ablation.
- Consensus document issued by multiple heart rhythm associations outlining key treatment changes.
- Utilized recent clinical trial data and technological advancements in AF ablation.
- Catheter ablation demonstrated superiority to antiarrhythmic drugs in preventing arrhythmia recurrences, improving symptoms, and delaying AF progression in AAD-naïve patients with recurrent paroxysmal AF, with similar adverse event rates.
Structured PICO
Does catheter ablation prevent arrhythmia recurrences and improve symptoms compared to antiarrhythmic drugs in symptomatic, AAD-naïve patients with recurrent paroxysmal AF?
P
Population
Patients undergoing AF ablation, specifically symptomatic, AAD-naïve patients with recurrent paroxysmal AF
I
Intervention
Catheter and surgical ablation of atrial fibrillation
C
Comparator
Antiarrhythmic drugs (AADs)
O
Outcome
Arrhythmia recurrences, patients' symptoms, and AF progression
The 2024 EHRA/HRS/APHRS/LAHRS consensus document establishes catheter ablation as the preferred first-line rhythm control therapy over AADs for symptomatic, AAD-naïve patients with recurrent paroxysmal AF.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Ablation is the most effective way to prevent recurrences of atrial fibrillation and delay progression to more advanced forms. Pioneering techniques have emerged since the previous consensus in 2017, requiring new advice on who should receive this procedure and how to perform it in the safest and most effective manner.”
“Unfortunately, we don't have any data regarding the adjunctive ablation strategy on top of PVI that could prove consistently helpful in patients with persistent atrial fibrillation.”
“Technological innovations have made catheter ablation safer and more effective than ever before. For example, we now have pulsed field ablation which uses high energy electrical pulses to treat atrial fibrillation without damaging the nerves or oesophagus.”
Implication
Supports first-line catheter ablation in symptomatic AAD-naïve paroxysmal AF; confirms recent RCT superiority and updates 2024 consensus guidelines.
Abstract
The 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society consensus statement on catheter and surgical ablation of atrial fibrillation (AF) summarizes recent clinical trial data and technological advancements in AF ablation.1 It also provides updated clinical guidance for managing patients undergoing AF ablation. The following decalogue outlines the key changes included in this joint document (Figure 1). ... Randomized controlled clinical trials (RCTs) have documented that catheter ablation is superior to antiarrhythmic drugs (AADs) in preventing arrhythmia recurrences, improving patients’ symptoms and delaying AF progression to more advanced forms in symptomatic, AAD-naïve patients with recurrent paroxysmal AF, with a similar risk of adverse events. Therefore, catheter ablation should be preferred over AADs as first-line rhythm control therapy in this patient category.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Tzeis et al. (2025) conducted a review in Atrial fibrillation. Catheter ablation vs. Antiarrhythmic drugs (AADs) was evaluated. Catheter ablation is superior to antiarrhythmic drugs in preventing arrhythmia recurrences and delaying AF progression in symptomatic, AAD-naïve patients with recurrent paroxysmal AF.